Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: intermediate pre-test probability
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
No patient-level data are analyzed; instead, illustrative figures present the proposed workflow and anticipated performance benchmarks. If validated in multi-center studies, this framework could improve diagnostic accuracy, reduce avoidable interventions, and enable more personalized lung cancer care pathways.
Indeterminate pulmonary nodules are a frequent and challenging finding in both screening and incidental imaging.
APA
Khalpey Z, Pilli S (2026). Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.. Cureus, 18(2), e104310. https://doi.org/10.7759/cureus.104310
MLA
Khalpey Z, et al.. "Pilli Kai Score: A Proposed Digital Twin Framework Integrating Radiomics and Biomarkers for Enhanced Lung Nodule Risk Stratification.." Cureus, vol. 18, no. 2, 2026, pp. e104310.
PMID
41909290 ↗
Abstract 한글 요약
Indeterminate pulmonary nodules are a frequent and challenging finding in both screening and incidental imaging. Existing clinical prediction models provide structured estimates of malignancy risk but remain limited in precision, particularly for patients with intermediate pre-test probability. This technical report proposes the Pilli Kai Score, a digital twin framework that integrates clinical variables, radiomic features, blood-based biomarkers, and positron emission tomography (PET) data into a unified probability estimate for malignancy. The framework outlines a multi-modal modeling strategy incorporating validated clinical predictors, standardized radiomics, biomarkers evaluated in pulmonary nodule populations, and PET categories when available. Prespecified validation targets include strong calibration across risk strata, an area under the receiver operating characteristic (ROC) curve exceeding 0.85, and a high negative predictive value to safely defer invasive procedures in benign disease, with comparative evaluation against established clinical models. No patient-level data are analyzed; instead, illustrative figures present the proposed workflow and anticipated performance benchmarks. If validated in multi-center studies, this framework could improve diagnostic accuracy, reduce avoidable interventions, and enable more personalized lung cancer care pathways.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening.
- Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.
- Global economic differences in modern glioblastoma care - a systematic review.
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.
- Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
- Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison.